Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
94 participants
OBSERVATIONAL
2025-04-15
2025-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis 1: Prediabetes and Type 2 Diabetes Negatively Affect Cognitive Status in Geriatric Individuals.
Hypothesis 2: Physical Function Loss is More Pronounced in Individuals with Prediabetes and Type 2 Diabetes.
Hypothesis 3: Fatigue Level Will Increase in Geriatric Individuals with Prediabetes and Type 2 Diabetes.
Hypothesis 4: There Will Be a Correlation Between the Effects of Prediabetes and Type 2 Diabetes on Cognitive Status, Physical Function and Fatigue.
Hypothesis 5: Severity of Diabetes (Prediabetes vs. Type 2 Diabetes) Will Create Differences in Cognitive, Physical and Fatigue Status.
Prediabetic, diabetic and healthy volunteers constitute the universe of the study. There will be 4 different groups in the study. These groups are; those with normal range of Hemoglobin A1c Levels (HbA1c) between 4% and 5.6% for people without diabetes (Healthy), those with HbA1c level between 5.7% and 6.4%, those with prediabetes (Impaired Glucose Tolerance), those with 6.5% - 7.5% and those with HbA1c level above 7.5. Cognitive status, physical functions, dual task performance, motor motor and motor cognitive performances, fatigue, reaction reactions, directional skills of elderly individuals will be compared between these groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Intensive Monitoring of Patients With Poorly Controlled Type 2 Diabetes With Different Glycemic Background
NCT06385899
Comparison of Cognitive and Motor Dual Task Performance in Individuals With Prediabetes and Diabetes
NCT05203042
Dual Task Performance and Type II Diabetes Mellitus
NCT07107620
Cognitive Functions and BDNF in T2DM and Prediabetes Patients
NCT05654727
The Short and Long-term Effects of Low Advanced Glycation End Product* Diet
NCT06005519
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy
The normal range for Hemoglobin A1c Levels (HbA1c) for people without diabetes (Healthy) is those with an HbA1c level between 4% and 5.6%,
No interventions assigned to this group
A prediabetes (Impaired Glucose Tolerance)
those with a prediabetes (Impaired Glucose Tolerance) level between 5.7% and 6.4%
No interventions assigned to this group
Those with type 2 DM (controlled)
those with a HbA1c Levels of 6.5% - 7.5%
No interventions assigned to this group
Those with type 2 DM (uncontrolled)
those with an HbA1c level above 7.5
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* those with HbA1c level between 5.7% and 6.4%, those with prediabetes (Impaired Glucose Tolerance),
* those with 6.5% -7.5% level and
* those with HbA1c level above 7.5
* criteria are being 60 years of age and older,
Exclusion Criteria
* uncontrolled thyroid disease,
* those with vitamin B12, folic acid deficiency and anemia,
* those with uncontrolled hypertension,
* those with nephropathy and retrophy,
* those with any neuropsychological disorder, a history of alcohol, substance or drug addiction,
* those using any neurological or psychological medication (anticonvulsant drugs, antidepressants, anxiolytics, etc.),
* those with Alzheimer's and Parkinson's disease,
* those with cancer,
* those with lung disease
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uşak University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kevser Gürsan
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kevser Gursan, Dr.
Role: PRINCIPAL_INVESTIGATOR
Uşak University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uşak Education and Research Hospital
Uşak, Uşak, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
562-562-11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.